Canopy Growth Corp. surged 49% after the announcement, while Aurora Cannabis Inc. and Tilray Brands Inc. soared 32% and 39%, respectively.
The Associated Press, citing five sources familiar with the matter, reported the DEA’s proposal would recognize the medical uses of cannabis and acknowledge it has less potential for abuse than other, more dangerous drugs.
However, it would not legalize marijuana for recreational use.
Currently, marijuana is listed as a Schedule I drug in the U.S., alongside heroin and LSD, but would be reclassified as a Schedule III drug, alongside ketamine and some anabolic steroids.
The reclassification of the drug in the U.S. could lessen risks for cannabis companies that operate south of the border and potentially improve investor appetite for cannabis stocks.
Companies in this story: (TSX:TLRY, TSX:ACB, TSX:WEED)
More about investing:
The Canadian Press
Source link
